Document is current
Any future updates will be listed below
-
Authors
Pless, Silvan https://orcid.org/0000-0002-9660-9077
Woelfle, Tim https://orcid.org/0000-0001-6279-4158
Lorscheider, Johannes https://orcid.org/0000-0003-1100-2506
Wiencierz, Andrea https://orcid.org/0000-0001-8786-7915
Reyes, Óscar https://orcid.org/0000-0003-0169-297X
Luque, Carlos https://orcid.org/0009-0008-2668-9826
Calabrese, Pasquale https://orcid.org/0000-0003-3347-5187
Granziera, Cristina https://orcid.org/0000-0002-4917-8761
Kappos, Ludwig
-
Funding
Funding for this research was provided by:
University of Basel
- License Information
-
More Information
Article History
Received: 9 July 2024
Revised: 24 September 2024
Accepted: 27 September 2024
First Online: 15 January 2025
Declarations
:
: Tim Woelfle has nothing to disclose. Johannes Lorscheider’s institution has received research grants from Novartis, Biogen, and Innosuisse as well as honoraria for advisory boards and/or speaking fees from Novartis, Roche, and Teva. Andrea Wiencierz has nothing to disclose. Oscar Reyes is lead data scientist of Indivi Ltd. Carlos Luque is a data scientist of Indivi Ltd. Pasquale Calabrese has received honoraria for speaking at scientific meetings, serving at scientific advisory boards, and consulting activities from: Abbvie, Actelion, Almirall, Bayer-Schering, Biogen Idec, Celgene, EISAI, Genzyme, Lundbeck, Merck Serono, Novartis, Pfizer, Teva, and Sanofi-Aventis. His research is also supported by the Swiss Multiple Sclerosis Society and the Swiss National Research Foundation. The University Hospital Basel (USB) and the Research Center for Clinical neuroimmunology and Neuroscience (RC2NB), as the employers of Cristina Granziera, have received the following fees which were used exclusively for research support from Siemens, GeNeuro, Genzyme-Sanofi, Biogen, Roche. They also have received advisory board and consultancy fees from Actelion, Genzyme-Sanofi, Novartis, GeNeuro, Merck, Biogen and Roche; as well as speaker fees from Genzyme-Sanofi, Novartis, GeNeuro, Merck, Biogen and Roche. Pasquale Calabrese has received honoraria for speaking at scientific meetings, serving at scientific advisory boards, and consulting activities from Abbvie, Actelion, Almirall, Bayer-Schering, Biogen, EISAI, Lundbeck, Merck Serono, Novartis, Sanofi-Aventis, and Teva. He has also received research grants from the Swiss Multiple Sclerosis Society (SMSG) and the Swiss National Research Foundation. Ludwig Kappos has received no personal compensation. His institution (University Hospital Basel/Foundation Clinical Neuroimmunology and Neuroscience Basel) has received the following exclusively for research support: steering committee, advisory board, and consultancy fees (Abbvie, Actelion, Auriga Vision AG, Biogen, Celgene, Desitin, Eli Lilly, EMD Serono, Genentech, Genzyme, Glaxo Smith Kline, Janssen, Japan Tobacco, Merck, Minoryx, Novartis, Roche, Sanofi, Santhera, Senda, Shionogi, Teva, and Wellmera; speaker fees (Celgene, Janssen, Merck, Novartis, and Roche); support for educational activities (Biogen, Desitin, Novartis, Sanofi and Teva); license fees for Neurostatus products; and grants (European Union, Innosuisse, Novartis, Roche Research Foundation, Swiss MS Society and Swiss National Research Foundation).
